Download or read book New Frontiers in Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Diseases written by Konstantinos Papamichael and published by Mdpi AG. This book was released on 2023-12-26 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: Therapeutic drug monitoring (TDM) has emerged as a useful tool for optimizing biological treatment in patients with inflammatory bowel disease (IBD) and other immune-mediated inflammatory diseases (IMID). Reactive TDM has rationalized the management of primary non-response and secondary loss of response to biologics, while cumulative evidence suggests that proactive TDM is efficacious for optimizing anti-tumour necrosis factor (anti-TNF) therapy in patients with IBD. Proactive TDM can be very useful for optimizing biological therapy in specific IBD populations, such as pregnant women as well as patients with perianal fistulizing Crohn's disease and acute severe ulcerative colitis who are characterized by high drug clearance. Preliminary data suggest that proactive TDM may also have a role in de-escalating anti-TNF therapy in patients in clinical remission including stopping the immunomodulator when combined with anti-TNF therapy. However, several knowledge gaps and limitations hinder the wide implementation of TDM in clinical practice, including the optimal drug concentration to target the lag time between sampling and results and the lack of harmonization of TDM assays. Recent advances regarding the role of TDM include the use of rapid point-of-care assays and the incorporation of model-informed precision dosing. The aim of this Special Issue is to highlight the clinical utility of TDM and discuss the barriers and recent advances of TDM of biologics in IBD and other IMID.
Download or read book Biologics in Inflammatory Bowel Disease written by Scott Plevy Associate Professor of Medicine Division of Gastroenterology and published by Oxford University Press, USA. This book was released on 2010 with total page 64 pages. Available in PDF, EPUB and Kindle. Book excerpt: SERIES OVERVIEW: The Oxford American Pocket Notes are a series of ultra-concise, small-format books for healthcare professionals on topics related to the diagnosis, treatment and management of various medical conditions. Each title typically features an outline of key points, guidelines and tools such as patient assessments and treatment algorithms, for a specific area of medical diagnosis and/or management. Highly practical in format, content and style, the Pocket Notes serve as a quick, easily accessible point-of-care reference for busy practitioners. In effect, they are miniature versions of the Oxford American Medical Library and Oxford American Handbooks in Medicine, capturing the key essentials needed for appropriate assessment and treatment. Inflammatory bowel disease (IBD) is a gastrointestinal condition which causes inflammation of the lining of the digestive tract. This disease affects an estimated one million Americans, usually in the forms of ulcerative colitis (UC) and Crohn's disease (CD). These two diseases have similar symptoms and are often confused for one another. Crohn's disease can occur anywhere in the digestive tract, often spreading deep into the layers of affected tissues, but ulcerative colitis usually affects only the innermost lining (mucosa) of the large intestine and rectum. IBD patients suffer from severe diarrhea and abdominal pain, and may experience other complications, such as arthritis and kidney stones, that affect the body beyond the intestinal tract. The Oxford American Pocket Notes: Biologics in Inflammatory Bowel Disease is a practical guide to the safe administration of biological agents to treat inflammatory gastrointestinal illnesses. This ultra-concise and practical volume focuses on tumor necrosis factor (TNF) blocking therapy (TNF blocker), an important new class of biologic therapy indicated for the treatment of several rheumatic and other auto-immune disorders, including Crohn's disease and ulcerative colitis. This uniquely compact and affordable book features evidence-based discussion and guidelines on the mechanism of action, dosing, administration and safety considerations for the biologic agents approved to treat CD and UC, thus providing practicing physicians with easily accessible tools and insights on the use of these drugs in a daily practice setting. Culled from the pages of Handbook of Biological Therapy, this portable guide is a valuable resource for gastroenterologists, primary care physicians and other healthcare providers involved in the management of these chronic but treatable diseases.
Download or read book Biologics in Inflammatory Bowel Disease An issue of Gastroenterology Clinics of North America written by Edward V. Loftus Jr and published by Elsevier Health Sciences. This book was released on 2014-09-28 with total page 257 pages. Available in PDF, EPUB and Kindle. Book excerpt: By the time this issue of Gastroenterology Clinics of North America is released, it will have been 16 years since infliximab was approved by the US Food and Drug Administration for the treatment of moderate to severe Crohn disease. Not only have we come a long way in understanding the efficacy and safety of infliximab, we are beginning to understand how and when to use the drug. Furthermore, as of this writing, we have five other biologic agents approved for either Crohn disease or ulcerative colitis, and there are many more molecules currently in drug development for these indications. In this issue,the Editors have assembled a collection of experts to provide the most cutting-edge information on the status of biologic therapy for inflammatory bowel disease.
Download or read book Treatment of Inflammatory Bowel Disease with Biologics written by Adam S. Cheifetz and published by Springer. This book was released on 2017-11-09 with total page 337 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book is a concise yet comprehensive overview of the use of biologics for the treatment of Crohn’s disease and ulcerative colitis. The volume details how best to utilize these medications in order to optimize their efficacy and safety, as well as how to understand, recognize, and treat complications that may arise from using biologics to treat IBD. The text also focuses on new data, novel biologics, and biosimilars of this rapidly expanding field. Written by experts in the field, Treatment of Inflammatory Bowel Disease with Biologics is a valuable resource for gastroenterologists, allied health professionals, fellows, and trainees who treat patients with inflammatory bowel disease.
Download or read book New Concepts in Inflammatory Bowel Disease written by Batool Mutar Mahdi and published by BoD – Books on Demand. This book was released on 2018-03-21 with total page 110 pages. Available in PDF, EPUB and Kindle. Book excerpt: Inflammatory bowel disease is a chronic immune-mediated inflammation of the gastrointestinal tract of unknown origin, which includes Crohn's disease, ulcerative colitis, and inflammatory bowel disease of unclassified type. It is associated with different intestinal and extraintestinal manifestations like different neurological and psychiatric disorders. Histology is an important tool in the diagnosis and prognosis of inflammatory bowel disease and has an increasing part in patients' management. The objective of treatment is to make and keep long-lasting remission by immunosuppressive treatment like corticosteroids, thiopurines, and monoclonal antibodies directed against tumor necrosis factor alpha. Therapeutic drug monitoring of thiopurines by measuring levels of their metabolites has been proposed as a potentially effective tool in optimizing therapy in inflammatory bowel disease. Diets and their components influence microbiota of the intestine, function of the epithelial barrier, immune response, and other factors that have an important role in development and treatment of inflammation in the gut mucosa.
Download or read book Biologics in Inflammatory Bowel Disease written by Scott Plevy and published by OUP USA. This book was released on 2012-10 with total page 56 pages. Available in PDF, EPUB and Kindle. Book excerpt: Biologics in Inflammatory Bowel Disease is a practical guide to the safe administration of biological agents to treat inflammatory gastrointestinal illnesses. This ultraconcise and practical volume focuses on tumour necrosis factor (TNF) blocking therapy (TNF blocker), and important new class of biologic therapy indicated for the treatment of several rheumatic and other auto-immune disorders, including Crohn's disease and ulcerative colitis.
Download or read book Therapeutic Advances in Inflammatory Bowel Disease Current Therapies and Future Directions written by Giulia Roda and published by Frontiers Media SA. This book was released on 2023-10-23 with total page 150 pages. Available in PDF, EPUB and Kindle. Book excerpt: Inflammatory bowel diseases (IBD), are chronic and progressive diseases. Long-term complications are demolition surgery and colon-rectal cancer (CRC). A treat-to-target approach aims to modify the natural course of these diseases. Targets are pre-defined therapeutic goals demonstrated to prevent end-organ disfunction and disability in the long-term period. According to the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) indications, mucosal healing (MH) and clinical remission are the main targets in IBDs. Recently, the concept of remission and evidence on new targets included histological remission and transmural healing as future new targets. It remains controversial whether achieving these targets is associated with significantly better long-term disease outcomes. In this Research Topic, we aim to systematically review current evidence and future perspectives on therapeutic targets in IBD including mucosal and transmural healing.
Download or read book Alternatives in the Management of Inflammatory Bowel Disease written by Adriaan Volkers and published by . This book was released on 2023 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: "This thesis consists of clinical research on optimization of the management of inflammatory bowel diseases (IBD) by exploring alternatives for monitoring and treatment of IBD. Furthermore, research was conducted on the implications of SARS-CoV-2 for patients with various immune-mediated inflammatory diseases (IMID), including IBD.One aspect of the investigation involved assessing therapy response in Crohn's disease (CD) through pan-enteric capsule endoscopy (Pan-CE), enabling observation of the entire small intestine and colon. Pan-CE demonstrated its efficacy in measuring changes in endoscopic disease activity among CD patients. Additionally, four faecal biomarkers of intestinal inflammation were compared in paediatric Crohn's disease cases: faecal calprotectin (FCP), chitinase 3-like-1 protein (CHI3L1), S100A12, and osteoprotegerin (OPG). Among these biomarkers, FCP proved to be the most suitable indicator of clinical and endoscopic disease activity in children with CD. In another study, a novel POCT (point-of-care testing) device was validated for measuring concentrations of infliximab, adalimumab, and CRP in capillary blood obtained through finger-prick, as well as FCP levels in stool samples. A randomized controlled trial (RCT) compared placebo to mercaptopurine, with mercaptopurine dosing guided by therapeutic drug monitoring. Mercaptopurine was more effective, as after one year of treatment, a significantly higher number of patients on mercaptopurine achieved clinical, endoscopic, and histological remission. Subsequently, a switch from intravenous vedolizumab maintenance treatment to subcutaneous vedolizumab injections was investigated. Vedolizumab concentration in the blood increased after the transition from infusions to vedolizumab injections, with a correlation between lower disease activity and higher serum drug levels. Utilizing data from a comprehensive observational study on SARS-CoV-2 in immune-mediated inflammatory diseases, the long-term humoral immune response was explored in patients with confirmed previous SARS-CoV-2 infection. Patients treated with anti-TNF agents (including infliximab or adalimumab) had a lower seropositivity rate following a prior infection. Approximately one-quarter of patients reported increased IMID activity, resulting in treatment intensification in only two percent of these cases."--
Download or read book Crohn s Disease and Ulcerative Colitis written by Daniel C. Baumgart and published by Springer. This book was released on 2017-03-01 with total page 671 pages. Available in PDF, EPUB and Kindle. Book excerpt: This new edition is a unique combined resource for physicians and scientists addressing the needs of both groups. In addition to stimulating exchange and collaboration and shortening the path between discovery and application of new knowledge, the book helps clinicians understand new therapeutic concepts from their origins. The volume serves as a comprehensive guide to the current diagnostic modalities, including enhanced imaging techniques such as MRI and CT enterography, virtual colonoscopy, ultrasound, and endomicroscopy, as well as conventional and complex immunomodulatory principles. The latest edition also includes revised chapters from the previous edition, as well as new chapters reflecting current developments in the field. Written by experts in their field, Crohn’s Disease and Ulcerative Colitis: From Epidemiology and Immunobiology to a Rational Diagnostic and Therapeutic Approach, Second Edition is of great value to gastroenterologists, surgeons, internists, pediatricians and gynecologists trainees, as well as all those involved in Crohn’s disease, ulcerative colitis, and related autoimmune disorders.
Download or read book Induction of immune tolerance Addressing unmet medical need in immune mediated diseases and immune responses to biologics written by Amy Rosenberg and published by Frontiers Media SA. This book was released on 2023-09-25 with total page 190 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Biologics Biosimilars and Biobetters written by Iqbal Ramzan and published by John Wiley & Sons. This book was released on 2021-02-03 with total page 328 pages. Available in PDF, EPUB and Kindle. Book excerpt: A comprehensive primer and reference, this book provides pharmacists and health practitioners the relevant science and policy concepts behind biologics, biosimilars, and biobetters from a practical and clinical perspective. Explains what pharmacists need to discuss the equivalence, efficacy, safety, and risks of biosimilars with physicians, health practitioners, and patients about Guides regulators on pragmatic approaches to dealing with these drugs in the context of rapidly evolving scientific and clinical evidence Balances scientific information on complex drugs with practical information, such as a checklist for pharmacists
Download or read book Immunogenicity of Proteins Used as Therapeutics written by Amy Rosenberg and published by Frontiers Media SA. This book was released on 2020-12-28 with total page 328 pages. Available in PDF, EPUB and Kindle. Book excerpt: Topic Editor Susan Richards is an employee of Sanofi and owns stock in the corporation. Topic Editor Bernard Maillere declares economic support from pharmaceutical companies (Novartis, Sanofi, and UCB) in the frame of collaborations aiming to evaluate the recognition by human T cells of therapeutic proteins and antibodies.
Download or read book Right Heart Pathology written by Silviu Ionel Dumitrescu and published by Springer. This book was released on 2018-05-31 with total page 935 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book reviews the management of right heart diseases, incorporating etiology, physiopathology, prevention, diagnosis and treatment. The frequency of this pathology has increased in recent years, while techniques for its treatment have evolved. This book therefore represents a complete, detailed and updated presentation of this pathology, reviewing the expanded treatment options while considering the management of patients in detail. Right Heart Pathology: From Mechanism to Management provides a comprehensive insight into right heart pathology, current diagnostic methods, treatments and postsurgical management. Written by experienced cardiologists and cardiovascular surgeons who have addressed significant issues in this topic area, it represents the essential reference in this specialty.
Download or read book Therapeutic Monoclonal Antibodies written by Zhiqiang An and published by John Wiley & Sons. This book was released on 2011-09-20 with total page 932 pages. Available in PDF, EPUB and Kindle. Book excerpt: 70-chapter authoritative reference that covers therapeutic monoclonal antibody discovery, development, and clinical applications while incorporating principles, experimental data, and methodologies. First book to address the discovery and development of antibody therapeutics in their entirety. Most chapters contain experimental data to illustrate the principles described in them. Authors provide detailed methodologies that readers can take away with them and use in their own laboratories.
Download or read book TNF Pathophysiology written by George Kollias and published by Karger Medical and Scientific Publishers. This book was released on 2010-01-01 with total page 223 pages. Available in PDF, EPUB and Kindle. Book excerpt: TNF is a multifunctional proinflammatory cytokine central to the development and homeostasis of the immune system and a regulator of cell activation, differentiation and death. Recent decades have seen an enormous scientific and clinical interest in the function of TNF in physiology and disease. A vast amount of data has been accumulated at the biochemical, molecular and cellular level, establishing TNF as a prototype for in-depth understanding of the physiological and pathogenic functions of cytokines. This volume covers several current aspects of TNF regulation and function, including transcriptional and posttranscriptional control mechanisms, cellular modes of action, signaling networks that mediate its effect, involvement in pathogenesis and clinical outcomes of TNF antagonists. It combines basic science at the molecular and cellular level with research in animal models of disease and clinical findings to provide a comprehensive review of recent developments in TNF biology. A thorough understanding of the mechanisms by which this key molecular player is produced and functions to regulate cell biology, immunity and disease postulates novel paradigms on how genes contribute to the development and physiology of biological systems.
Download or read book Inflammatory Bowel Disease written by Ramona Rajapakse and published by Springer Nature. This book was released on 2021-09-23 with total page 368 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book uses new thinking on precision medicine and the interplay of genetic factors, the microbiome, and external triggers to build on the core concepts of inflammatory bowel disease. It outlines the latest findings in targeting therapies to the individual patient with Crohn’s and colitis, management of chronic infections in the setting of immunomodulators and biologics, non-surgical therapy of dysplasia in colitis patients, and redefining and structuring the problematic pouch. In addition, this book features useful chapters dedicated to the economic aspects of IBD in an increasingly constrained healthcare system, as well as the patient experience and the role of subspecialist telemedicine care. Written by specialists and thought leaders in the field, Inflammatory Bowel Disease: Pathogenesis, Diagnosis and Management provides a concise but highly relevant account of the latest thinking and concepts in IBD.
Download or read book Pain Management and the Opioid Epidemic written by National Academies of Sciences, Engineering, and Medicine and published by National Academies Press. This book was released on 2017-09-28 with total page 483 pages. Available in PDF, EPUB and Kindle. Book excerpt: Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.
